BOARD OF DIRECTORS
Board of director profiles
Jo Patterson, CEO
Jo is a managing director and CEO with over 20 years in business and corporate strategy with exposure both in Australia and overseas. She has developed a number of businesses from start-up as well as driving established organisations towards growth and merger trajectories. She has been officially recognised as a successful business executive by winning a number of key business awards and her acumen is evidenced in the success of previous companies in the technology, advertising and health and beauty sectors.
Today, Jo has led Bod from its listing on ASX in October 2016, to a growth business expanding globally, inspiring innovation and developing products for the medical and consumer healthcare markets.
Mark Masterson, Non-Executive Chairman
Mark Masterson is a leading pharmaceutical executive with over 20 years’ experience throughout multiple geographies. He held a number of senior roles during his time with global healthcare giant, Abbott Laboratories (NYSE: ABT, market capitalisation: ~US$215Bn). At Abbott Laboratories, Mr Masterson held leadership positions across the USA, Europe, Asia and Australia. He was subsequently promoted to Vice President of Commercial Operations in Asia and became a Corporate Officer for the group.
Following his roles with Abbott Laboratories, Mr Masterson became Chief Executive Officer of I-MED, Australia’s largest private diagnostic imaging network. Mr Masterson concluded his four-year tenure at I-MED following the sale of the business to new owners and took up a position as Chairman of Medicines Australia. Medicines Australia is the leading representative body for discovery-driven pharmaceutical companies in Australia.
George Livery, Non-Executive Director
George Livery has close to 30 years’ experience in senior roles domestically and internationally. His high-level experience most notably culminated in roles with Swisse Wellness Group, where he began as a Commercial Director and subsequently was promoted to Director of Strategy & Corporate.
During his tenure with Swisse, Mr Livery was responsible for a broad range of initiatives including international business expansion, commercial contracts and agreements, third party and commercial branding opportunities as well as wholesaler and reseller compliance. Mr Livery was instrumental in negotiating the $1.67 billion transaction with Biostime (now H&H Group) and leading the corporate integration and strategy of the two companies post transaction.
David Baker, Non-Executive Director
Mr Baker is a commercial advisor and company director with over 40 years’ experience in law, investment banking, public company leadership and corporate governance.
He has deep industry knowledge across a range of sectors and a sophisticated understanding of financial markets. Mr Baker is a co-founder of Baker Cook Advisory which is a boutique provider of outsourced legal, commercial and governance advice and mediation services for corporations and government agencies.
Akash Bedi, Non-Executive Director
Mr Bedi is Chief Strategy & Operations Officer at Health & Happiness Group Limited. He is responsible for progressing strategy and business development opportunities within H&H Group, as well as leading strategic investments for NewH2, the company’s innovation arm. He has considerable experience in global start up investment, as well as the integration of high growth companies and technologies.
Hanno Cappon, Non-Executive Director
Mr Cappon is currently Chief Technology Officer at H&H, a position which he has held since January 2021. He has an extensive background in chemistry, life sciences, nutrition and health innovation and developing new consumer and healthcare solutions for commercialisation.
Mr Cappon’s previous senior roles with large international companies include VP R&D Nutritionals & Digestive Health at Bayer Consumer Health, Switzerland, as well as VP R&D Nutricia Medical Nutrition at leading multinational food company Danone Nutricia, Netherlands, amongst others.
Link Market Services Limited Level 12, 680 George Street SYDNEY NSW 2000
Nexia Sydney Audit Pty Ltd.
Principal place of business
Stock exchange listing
Level 1, 377 New South Head Road Double Bay NSW 2028
BOD shares are listed on the Australian Securities Exchange (ASX code: BOD)